SHIFT Newsroom · GLOBAL
UBT251 Injection Enters Phase 1a/1b Trials for Safety and Efficacy
A randomized, placebo-controlled study assesses the safety, pharmacokinetics, and pharmacodynamics of UBT251, a GLP-1/GIP/GCG receptor agonist injection.
Introduction to UBT251
UBT251 is under investigation as a GLP-1/GIP/GCG receptor agonist injection. A Phase 1a/1b study aims to evaluate its safety, pharmacokinetics, and pharmacodynamics.
Clinical Trials
The randomized, placebo-controlled Phase 1a/1b study is a crucial step in assessing UBT251's potential as a treatment.
What this means in the UK
As a potential treatment, UBT251's progression through clinical trials may offer future options for patients in the UK, pending regulatory approvals and NHS commissioning decisions.
Known facts
- UBT251 is a GLP-1/GIP/GCG receptor agonist injection in Phase 1a/1b clinical trials.